Huoleti Oy and Roche Oy have signed a co-operation agreement.
Following the agreement, Roche Oy will participate in Huoleti’s marketing efforts by boosting awareness of the company’s application and service among health care professionals and patient organisations. The first phase of the agreement extends until the end of 2019.
“This co-operation with the world’s largest cancer company offers us brand new channels and opportunities in Finland,” says Maria Lipsonen, COO of Huoleti Oy.
“Roche Oy wishes to support patients during their treatment and recovery,” explains Anssi Linnankivi, Medical Director at Roche Oy. “Huoleti-service offers patients everyday assistance in a novel and innovative way, and we are pleased to help implementing it.”
The Huoleti-service will first be tested in Finland in collaboration with patient organisations and health care professionals. Service will be developed on the basis of user feedback with the goal of preparing international distribution.
“Peer support is of great importance during a serious illness. We want to ensure that as many patient as possible receive support and help through the Huoleti-service to cope with everyday tasks. The importance of peer support – both emotionally and as an information channel – should be better recognised and acknowledged in health care. Our agreement with Roche Oy will lead to something unique, possibly also on a global scale, and we are eagerly waiting for the co-operation to begin,” says Maria Lipsonen.
HUOLETI Oy is a health technology start-up that is developing an innovative service offering for seriously ill patients and their families. The user-friendly service helps find peer support and assistance for everyday challenges. The company works closely with various organisations, the public and private sectors and users.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Further information and interview requests:
Anssi Linnankivi, Medical Director
+358 50 383 0832
Carita Savin, CEO
+358 40 562 1700
Maria Lipsonen, COO
+358 50 541 0780